Background: The Patient Benefit Index (PBI) is a recently developed instrument to assess patient satisfaction with treatment. It has been applied to only a limited number of psoriasis patients. Objective: Characterization of patient-reported outcomes (PRO) in patients with moderate to severe psoriasis Methods: 1,787 patients with plaque psoriasis were documented. Psoriasis Area and Severity Index (PASI), body surface area (BSA), Dermatology Life Quality Index (DLQI) and PBI were determined. Correlations were calculated and the persistence of PBI improvement and strength of treatment effect were evaluated. A regression analysis was performed to characterize predictors of PBI and DLQI improvements. Results: Significant correlations exist between ΔPASI/ΔBSA and ΔDLQI. Also, DLQI and PBI are correlated. Improvement in the skin condition has a positive and sustainable impact on all need dimensions of the PBI. The best early predictor for PBI was PASI 75 at treatment week 8, relevant factors predicting quality of life were PBI/subscale 4, (reducing physical impairment), ΔBSA and ΔPASI. Conclusion: Improvement in skin condition correlates with improvements in quality of life in patients with plaque psoriasis. Successful treatment leads to significant and sustainable patient benefit. While PBI subscale 4 is a good predictor for quality of life, more work is necessary to identify potential predictors for patient benefit.

Keywords:
Health-related quality of life, Patient-reported outcomes, Patient benefit index, Psoriasis
1.
Schaefer I, Rustenbach S, Zimmer L, Augustin, M: Prevalence of skin diseases in a cohort of 48,665 employees in Germany. Dermatology 2008;217:169–172.
2.
Augustin M, Reich K, Glaeske G, Schaefer I, Radtke M: Comorbidity and age-related prevalence of psoriasis – analysis of health insurance data in Germany. Acta Derm Venereol 2010;90:147–151.
3.
Krueger G, Koo J, Lebwohl M, Menter A, Stern RS, Rolstad T: The impact of psoriasis on quality of life – results of a 1998 National Psoriasis Foundation Patient-Membership Survey. Arch Dermatol 2001;137:280–284.
4.
Dubertret L, Mrowietz U, Ranki A, van de Kerkhof PC, Chimenti S, Lotti T, Schäfer G, EUROPSO Patient Survey group: European patient perspectives on the impact of psoriasis: the EUROPSO patient membership survey. Br J Dermatol 2006;155:729–736.
5.
EUROPSO: The EUROPSO psoriasis patient study: treatment history and satisfaction reported by 17,990 members of European psoriasis patient associations. Helsinki, EUROPSO, 2002. www.europso.eu/media/archive2/europso_survey_en.pdf.
6.
Bullinger M, Kirchberger I, Ware J: Der deutsche SF-36 Health Survey. Übersetzung und psychometrische Testung eines krankheitsübergreifenden Instruments zur Erfassung der gesundheitsbezogenen Lebensqualität. Z Gesundh Wiss 1995;3:21–36.
7.
Finlay A, Khan G: Dermatology Life Quality Index (DLQI) – a simple practical measure for routine clinical use. Clin Exp Dermatol 1994;19:210–216.
8.
Augustin M, Radtke MA, Zschocke I, Blome C, Behechtnejad J, Schäfer I, Reusch M, Mielke V, Rustenbach SJ: The Patient Benefit Index (PBI) – a novel approach in patient defined outcomes measurement for skin diseases. Arch Dermatol Res 2009;301:561–571.
9.
Blome C, Augustin A, Behechtnejad J, Rustenbach F: Dimensions of patient needs in dermatology: subscales of the patient benefit index. Arch Dermatol Res 2011;303:11–17.
10.
Blome C, Simianer S, Purwins S, Laass A, Rustenbach SF, Schaefer I, Radtke M, Augustin A: Time needed for treatment is the major predictor of quality of life in psoriasis. Dermatology 2010;221:154–159.
11.
de Korte J, Sprangers MAG, Mombers FMC, Bos JD: Quality of life in patients with psoriasis: a systematic literature review. J Investig Dermatol Symp Proc 2004;9:140–147.
12.
Gelfand JM, Feldman SR, Stern RS, Thomas J, Rolstad T, Margolis DJ: Determinants of quality of life in patients with psoriasis: a study from the US population. J Am Acad Dermatol 2004;51:704–708.
13.
Augustin M, Zschocke I, Lange S, Seidenglanz K, Amon U: Lebensqualität bei Hauterkrankungen: Vergleich verschiedener Lebensqualitäts-Fragebögen bei Psoriasis und atopischer Dermatitis (Quality of life in skin diseases: methodological and practical comparison of different quality of life questionnaires in psoriasis and atopic dermatitis). Hautarzt 1999;50:715–722.
14.
Augustin M, Krüger K, Radtke MA, Schwippl I, Reich K: Disease severity, quality of life and health care in plaque-type psoriasis: a multicenter cross-sectional study in Germany. Dermatology 2008;216:366–372.
15.
Augustin M, Lange S, Wenninger K, Seidenglanz K, Amon U, Zschocke I: Validation of a comprehensive Freiburg Life Quality Assessment (FLQA) core questionnaire and development of a threshold system. Eur J Dermatol 2004;14:107–113.
16.
Touw CR, Hakkaart-Van Roijen L, Verboom P, Paul C, Rutten FF, Finlay AY: Quality of life and clinical outcome in psoriasis patients using intermittent cyclosporin. Br J Dermatol 2001;144:967–972.
17.
Schäfer I, Hacker J, Rustenbach SJ, Radtke M, Franzke N, Augustin M: Concordance of the Psoriasis Area and Severity Index (PASI) and patient-reported outcomes in psoriasis treatment. Eur J Dermatol 2010;20w:62–67.
© 2011 S. Karger AG, Basel
2011
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.